Public Release: 13-Oct-2016
American Society of Nephrology
- Factors secreted by Oxalobacter formigenes, a bacterium that lives in the large intestine, can reduce urinary excretion of oxalate in mice. Such factors may therefore help prevent or treat kidney stones.
- Kidney stone disease is the second most prevalent kidney disease in United States after hypertension.
Washington, DC (October 13, 2016) — Researchers have discovered that factors secreted by gut bacteria might help prevent or treat kidney stones. The findings appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN).
Kidney stones can pose serious health problems for people and can increase their risks of developing chronic kidney disease and kidney failure. Oxalate is a small anion that can complex with calcium to form calcium oxalate kidney stones under certain conditions, and elevated urinary excretion of oxalate can be an indicator of increased risk. The intestines play a crucial role in oxalate balance, and Oxalobacter formigenes (Of) is an anaerobic bacterium that lives in the large intestine and utilizes oxalate as its exclusive energy source.
When studying this bacterium, Hatim Hassan, MD, PhD (University of Chicago) and his colleagues found that factors secreted by Of can stimulate oxalate transport by human intestinal cells grown in tissue culture. The team also revealed that the mechanisms of the observed stimulation involve the PKA signaling pathway and a protein transporter called SLC26A6. Importantly, Of factors reduced urinary oxalate excretion by >32.5% in mice by stimulating colonic oxalate secretion.
“Probiotic bacteria have several health benefits; however, the difficulties in determining intestinal bacterial bioavailability and biosafety concerns when administering live probiotics are potential problems facing current probiotics clinical applications. Developing probiotics-derived factors as novel therapeutic agents is an alternative approach that addresses such concerns,” said Dr. Hassan. “The fact that these factors retain their biological activity and can effectively reduce urinary oxalate excretion in mice indicates their significant potential as novel therapeutic agents, and provides a compelling reason for the aggressive pursuit of their characterization, which is currently underway.”
Study co-authors include Donna Arvans, BA, Yong-Chul Jung, PhD, Dionysios Antonopoulos, PhD, Jason Koval, MS, Ignacio Granja, Mohamed Bashir, PhD, Eltayeb Karrar, MD, Jayanta Roy-Chowdhury, MD, Mark Musch, PhD, John Asplin, MD, and Eugene Chang, MD.
Disclosures: John Asplin and Ignacio Granja are employed by Litholink Corporation, Laboratory Corporation of America® Holdings, Chicago, IL.
The article, entitled “Oxalobacter formigenes-Derived Bioactive Factors Stimulate Oxalate Transport by Intestinal Epithelial Cells,” will appear online at http://jasn.asnjournals.org/ on October 13, 2016; doi: 10.1681/ASN.2016020132.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, the American Society of Nephrology (ASN) has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has nearly 16,000 members representing 112 countries. For more information, please visit http://www.asn-online.org or contact us at 202-640-4660.